Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Bronchogenic × Magnetic Resonance Spectroscopy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 149 Breast Neoplasms 117 Lung Neoplasms 92 Carcinoma, Non-Small-Cell Lung 80 Brain Neoplasms 70 Glioblastoma 67 Neoplasm Metastasis 65 Glioma 58 Pancreatic Neoplasms 45 Carcinoma, Renal Cell 41 Neoplasms 38 Multiple Myeloma 38 Colorectal Neoplasms 36 Lymphoma, Large B-Cell, Diffuse 34 Melanoma 32 Squamous Cell Carcinoma of Head and Neck 31 Carcinoma, Hepatocellular 31 Ovarian Neoplasms 30 Urinary Bladder Neoplasms 28 Lymphoma 28 Astrocytoma 24 Sarcoma 23 Lymphoma, Follicular 23 Central Nervous System Neoplasms 23 Uterine Cervical Neoplasms 21 Triple Negative Breast Neoplasms 21 Oropharyngeal Neoplasms 21 Rectal Neoplasms 20 Mouth Neoplasms 20 Lymphoma, Non-Hodgkin 19

Interventions

Carboplatin 11 Pemetrexed 7 pembrolizumab 4 Paclitaxel 4 Cisplatin 4 durvalumab 3 Radiosurgery 3 selpercatinib 2 pralsetinib 2 osimertinib 2 atezolizumab 2 Gemcitabine 2 taletrectinib 1 repotrectinib 1 motexafin gadolinium 1 exemestane 1 entinostat 1 ceralasertib 1 cemiplimab 1 camrelizumab 1 belinostat 1 belagenpumatucel L 1 alectinib 1 Tyrosine Kinase Inhibitors 1 TNFSF10 protein, human 1 Radiotherapy 1 Platinum Compounds 1 Patient Reported Outcome Measures 1 Oncolytic Virotherapy 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00652769 2017-11-01

BOOST

University College London Hospitals

Phase 3 Completed

Carcinoma, Bronchogenic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡